Literature DB >> 28588884

Distinctive HLA-II association with primary biliary cholangitis on the Island of Sardinia.

Maria Grazia Clemente1,2, Fulvia Frau1, Matilde Bernasconi3, Maria Doloretta Macis1, Lucia Cicotto1, Giampaolo Pilleri3, Stefano De Virgiliis1, Paolo Castiglia4, Patrizia Farci5,6.   

Abstract

BACKGROUND: The HLA DRB1*08 allele associated with primary biliary cholangitis (PBC) among Caucasians is of low frequency in the Sardinian population.
OBJECTIVE: The aim of our study was to type a cohort of PBC patients from the island of Sardinia for HLA class II antigens.
METHODS: Twenty Sardinian patients affected by PBC, 14 with autoimmune hepatitis (AIH) and 89 healthy controls (HCs) were typed for HLA class II alleles by dot-blot analysis.
RESULTS: The PBC-associated HLA DRB1*08 allele was detected in none of the studied individuals. The DRB1*0301-DQB1*0201 was the prevalent HLA haplotype, detected in 19 (47.5%) out of 40 PBC haplotypes (OR = 3.0; 95% CI 1.5-6.2) and in 11 (39.3%) out of 28 AIH haplotypes (OR = 2.2; 95% CI 0.94-5.0), but in only 41 (23%) out of 178 HC haplotypes. Moreover, PBC patients showed an increased frequency of homozygosity for the DQB1*0201 allele (35% compared with 6.7% of the HCs; OR = 7.5; 95% CI 2.2-25.7). The frequency of the DRB1*11 allele in the PBC group was about half of that seen in the Sardinian HCs (7.5% vs 15.7%) (p = ns).
CONCLUSIONS: Our study confirmed the low frequency of the HLA DRB1*08 allele among Sardinians, either in the general population or PBC patients. The high prevalence of the HLA DRB1*0301-DQB1*0201 haplotype is a distinctive genetic feature of PBC among Sardinians. Our study strengthens the hypothesis that still unknown genetic, epigenetic, and environmental factors must be involved in the pathogenesis of different HLA-associated liver diseases, and it represents a pathfinder that warrants exploration in a future extensive study.

Entities:  

Keywords:  Immune-mediated liver diseases; autoimmune hepatitis; autoimmune liver diseases

Year:  2016        PMID: 28588884      PMCID: PMC5446142          DOI: 10.1177/2050640616665030

Source DB:  PubMed          Journal:  United European Gastroenterol J        ISSN: 2050-6406            Impact factor:   4.623


  23 in total

1.  The distribution of HLA class II haplotypes reveals that the Sardinian population is genetically differentiated from the other Caucasian populations.

Authors:  R Lampis; L Morelli; S De Virgiliis; M Congia; F Cucca
Journal:  Tissue Antigens       Date:  2000-12

2.  On estimating the relation between blood group and disease.

Authors:  B WOOLF
Journal:  Ann Hum Genet       Date:  1955-06       Impact factor: 1.670

3.  Multiple sclerosis in Sardinia is associated and in linkage disequilibrium with HLA-DR3 and -DR4 alleles.

Authors:  M G Marrosu; M R Murru; G Costa; F Cucca; S Sotgiu; G Rosati; F Muntoni
Journal:  Am J Hum Genet       Date:  1997-08       Impact factor: 11.025

Review 4.  Autoimmune hepatitis--Update 2015.

Authors:  Michael P Manns; Ansgar W Lohse; Diego Vergani
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

5.  HLA-DQB1*0201 homozygosis predisposes to severe intestinal damage in celiac disease.

Authors:  Rita-Désirée Jores; Fulvia Frau; Francesco Cucca; Maria Grazia Clemente; Sandra Orrù; Marco Rais; Stefano De Virgiliis; Mauro Congia
Journal:  Scand J Gastroenterol       Date:  2007-01       Impact factor: 2.423

Review 6.  Genetic and familial considerations of primary biliary cirrhosis.

Authors:  A Tanaka; A T Borchers; H Ishibashi; A A Ansari; C L Keen; M E Gershwin
Journal:  Am J Gastroenterol       Date:  2001-01       Impact factor: 10.864

Review 7.  Does the "hygiene hypothesis" provide an explanation for the high prevalence of multiple sclerosis in Sardinia?

Authors:  Stefano Sotgiu; Maura Pugliatti; Alessandra Sotgiu; Alessandra Sanna; Giulio Rosati; Sotgiu Stefano; Pugliatti Maura; Sotgiu Alessandra; Sanna Alessandra; Rosati Giulio
Journal:  Autoimmunity       Date:  2003-08       Impact factor: 2.815

8.  Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment.

Authors:  Carlo Selmi; Marlyn J Mayo; Nancy Bach; Hiromi Ishibashi; Pietro Invernizzi; Robert G Gish; Stuart C Gordon; Harlan I Wright; Bruce Zweiban; Mauro Podda; M Eric Gershwin
Journal:  Gastroenterology       Date:  2004-08       Impact factor: 22.682

Review 9.  Epigenetics and Primary Biliary Cirrhosis: a Comprehensive Review and Implications for Autoimmunity.

Authors:  Yu-Qing Xie; Hong-Di Ma; Zhe-Xiong Lian
Journal:  Clin Rev Allergy Immunol       Date:  2016-06       Impact factor: 8.667

10.  Human leukocyte antigen polymorphisms in Italian primary biliary cirrhosis: a multicenter study of 664 patients and 1992 healthy controls.

Authors:  Pietro Invernizzi; Carlo Selmi; Francesca Poli; Sara Frison; Annarosa Floreani; Domenico Alvaro; Piero Almasio; Floriano Rosina; Marco Marzioni; Luca Fabris; Luigi Muratori; Lihong Qi; Michael F Seldin; M Eric Gershwin; Mauro Podda
Journal:  Hepatology       Date:  2008-12       Impact factor: 17.425

View more
  4 in total

Review 1.  Genetics and epigenetics in the pathogenesis of primary biliary cholangitis.

Authors:  Satoru Joshita; Takeji Umemura; Eiji Tanaka; Masao Ota
Journal:  Clin J Gastroenterol       Date:  2017-11-20

2.  Pernicious anemia associated with cryptogenic cirrhosis: Two case reports and a literature review.

Authors:  Xin Yan; Runping Gao; Yulin Hu; Jinglan Jin
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.889

Review 3.  HLA, gut microbiome and hepatic autoimmunity.

Authors:  Benedetta Terziroli Beretta-Piccoli; Giorgina Mieli-Vergani; Diego Vergani
Journal:  Front Immunol       Date:  2022-08-18       Impact factor: 8.786

Review 4.  New insights on the role of human leukocyte antigen complex in primary biliary cholangitis.

Authors:  Giacomo Mulinacci; Andrea Palermo; Alessio Gerussi; Rosanna Asselta; Merrill Eric Gershwin; Pietro Invernizzi
Journal:  Front Immunol       Date:  2022-08-31       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.